Cargando…
Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
We performed a pairwise and network meta-analysis to compare pathological complete response (pCR) among neoadjuvant chemotherapy in patients with triple-negative breast cancer. We searched PubMed for randomized clinical trials between January 1, 2000 and December 1, 2020. Abstracts from meetings wer...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606982/ https://www.ncbi.nlm.nih.gov/pubmed/34806458 http://dx.doi.org/10.1177/00469580211056213 |
_version_ | 1784602454637150208 |
---|---|
author | Weng, Zeng-Jie Wu, Sheng-Xi Luo, He-San Du, Ze-Sen Li, Xu-Yuan Lin, Jia-Zhou |
author_facet | Weng, Zeng-Jie Wu, Sheng-Xi Luo, He-San Du, Ze-Sen Li, Xu-Yuan Lin, Jia-Zhou |
author_sort | Weng, Zeng-Jie |
collection | PubMed |
description | We performed a pairwise and network meta-analysis to compare pathological complete response (pCR) among neoadjuvant chemotherapy in patients with triple-negative breast cancer. We searched PubMed for randomized clinical trials between January 1, 2000 and December 1, 2020. Abstracts from meetings were also searched. A frequentist random-effect model was applied to compare pCR and toxicities. The P-score was used to rank treatment effects. Nineteen trials with 16 treatments and 7794 patients were included. On the basis of SoC, the addition of carboplatin (OR = 1.82, 95% CI, 1.24 to 2.68, P < .01) and the addition of checkpoint inhibitors (OR = 1.69, 95% CI, 1.23 to 2.32, P < .01) increased pCR in pairwise meta-analysis; compared with paclitaxel, nab-paclitaxel did not improve pCR rates (OR = 1.81, 95% CI, .80 to 4.12, P = .16). The anthracycline-sparing regimen led to similar pCR compared with the anthracycline-containing regimen (OR = 1.50, 95% CI, .82 to 2.76, P = .19). In network meta-analysis, the addition of carboplatin plus a PD-1 inhibitor (pembrolizumab), carboplatin plus bevacizumab, and carboplatin plus veliparib ranked as the top three treatments for achieving pCR, with corresponding P-scores of .91, .84, and .72, respectively. Among patients with homologous recombination deficiency, the addition of carboplatin (OR = 1.31, 95% CI, .69 to 2.50, P = .41) or carboplatin plus PARP inhibitors (OR = 1.19, 95% CI, .58 to 2.47, P = .63) did not increase pCR. For triple-negative breast cancer, combining carboplatin with taxane-anthracycline-containing neoadjuvant chemotherapy could be the standard of care, and the combination containing checkpoint inhibitor is promising. However, their role in long-term oncologic outcome remains to be determined. |
format | Online Article Text |
id | pubmed-8606982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-86069822021-11-23 Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response Weng, Zeng-Jie Wu, Sheng-Xi Luo, He-San Du, Ze-Sen Li, Xu-Yuan Lin, Jia-Zhou Inquiry Systematic Review or Meta-Analysis We performed a pairwise and network meta-analysis to compare pathological complete response (pCR) among neoadjuvant chemotherapy in patients with triple-negative breast cancer. We searched PubMed for randomized clinical trials between January 1, 2000 and December 1, 2020. Abstracts from meetings were also searched. A frequentist random-effect model was applied to compare pCR and toxicities. The P-score was used to rank treatment effects. Nineteen trials with 16 treatments and 7794 patients were included. On the basis of SoC, the addition of carboplatin (OR = 1.82, 95% CI, 1.24 to 2.68, P < .01) and the addition of checkpoint inhibitors (OR = 1.69, 95% CI, 1.23 to 2.32, P < .01) increased pCR in pairwise meta-analysis; compared with paclitaxel, nab-paclitaxel did not improve pCR rates (OR = 1.81, 95% CI, .80 to 4.12, P = .16). The anthracycline-sparing regimen led to similar pCR compared with the anthracycline-containing regimen (OR = 1.50, 95% CI, .82 to 2.76, P = .19). In network meta-analysis, the addition of carboplatin plus a PD-1 inhibitor (pembrolizumab), carboplatin plus bevacizumab, and carboplatin plus veliparib ranked as the top three treatments for achieving pCR, with corresponding P-scores of .91, .84, and .72, respectively. Among patients with homologous recombination deficiency, the addition of carboplatin (OR = 1.31, 95% CI, .69 to 2.50, P = .41) or carboplatin plus PARP inhibitors (OR = 1.19, 95% CI, .58 to 2.47, P = .63) did not increase pCR. For triple-negative breast cancer, combining carboplatin with taxane-anthracycline-containing neoadjuvant chemotherapy could be the standard of care, and the combination containing checkpoint inhibitor is promising. However, their role in long-term oncologic outcome remains to be determined. SAGE Publications 2021-11-20 /pmc/articles/PMC8606982/ /pubmed/34806458 http://dx.doi.org/10.1177/00469580211056213 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Systematic Review or Meta-Analysis Weng, Zeng-Jie Wu, Sheng-Xi Luo, He-San Du, Ze-Sen Li, Xu-Yuan Lin, Jia-Zhou Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response |
title | Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response |
title_full | Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response |
title_fullStr | Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response |
title_full_unstemmed | Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response |
title_short | Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response |
title_sort | neoadjuvant chemotherapy in early triple-negative breast cancer: a pairwise and network meta-analysis of pathological complete response |
topic | Systematic Review or Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606982/ https://www.ncbi.nlm.nih.gov/pubmed/34806458 http://dx.doi.org/10.1177/00469580211056213 |
work_keys_str_mv | AT wengzengjie neoadjuvantchemotherapyinearlytriplenegativebreastcancerapairwiseandnetworkmetaanalysisofpathologicalcompleteresponse AT wushengxi neoadjuvantchemotherapyinearlytriplenegativebreastcancerapairwiseandnetworkmetaanalysisofpathologicalcompleteresponse AT luohesan neoadjuvantchemotherapyinearlytriplenegativebreastcancerapairwiseandnetworkmetaanalysisofpathologicalcompleteresponse AT duzesen neoadjuvantchemotherapyinearlytriplenegativebreastcancerapairwiseandnetworkmetaanalysisofpathologicalcompleteresponse AT lixuyuan neoadjuvantchemotherapyinearlytriplenegativebreastcancerapairwiseandnetworkmetaanalysisofpathologicalcompleteresponse AT linjiazhou neoadjuvantchemotherapyinearlytriplenegativebreastcancerapairwiseandnetworkmetaanalysisofpathologicalcompleteresponse |